A Two-part, Randomised, Placebo-controlled Study to Investigatethe Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single Doses of Inhaled GSK1995057 in Healthy Subjects

Trial Profile

A Two-part, Randomised, Placebo-controlled Study to Investigatethe Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single Doses of Inhaled GSK1995057 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs GSK 1995057 (Primary)
  • Indications Acute lung injury; Adult respiratory distress syndrome
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Jan 2018 Dose escalating cohorts in part 1 were conducted at the PAREXEL International Clinical Pharmacology Research Unit, Harrow, UK and part 2 was carried out at Celerion Clinical Pharmacology Unit, Belfast, UK.
    • 29 Jan 2018 Results developing a potent and selective antagonist of TNFR1 (GSK1995057) using a novel domain antibody therapeutic and assessed its efficacy in vitro, in vivo and by taking patient data from this clinical trial, published in the Thorax.
    • 18 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top